 |
| (Source: Eisai) |
Korea's Boryung has successfully invalidated a Korean patent held by Japan's Eisai R&D Management Co. relating to an antitumor agent for thyroid cancer.
On March 27, 2025, the Korean Intellectual Property Trial and Appeal Board (IPTAB) invalidated claims 1 through 3 of Korean Patent No. 1470653, titled "Antitumor Agent for Thyroid Cancer." Boryung had initially filed the invalidation trial in November 2022, targeting the same claims.
The invalidated patent describes a pharmaceutical composition and treatment method for diseases including medullary thyroid carcinoma, papillary thyroid carcinoma, multiple endocrine neoplasia types IIA and IIB, familial and sporadic forms of thyroid cancer, Hirschsprung’s disease, pheochromocytoma, parathyroid hyperplasia, and mucosal neuroma of the digestive tract.
Notably, Eisai R&D Management had filed a separate scope confirmation trial in October 2024 against Boryung, asserting that Boryung's product infringed the same claims—1 through 3—of the patent. The board's latest decision invalidates exactly those asserted claims.
Eisai may appeal the IPTAB’s invalidation decision by filing a cancellation action with the Korean Patent Court.
Separately, Daewoong Pharmaceutical had also filed an invalidation trial against the same patent in December 2022 but later withdrew its petition in May 2023.
By PatenTrip
Comments
Post a Comment